On Demand 2024 Monday General Sessions

This course includes the following sessions from Monday's program:

  • Plenary: The 2025 Severe or Difficult-to-Control Asthma Practice Parameter: A Sneak Preview
  • Variation in Practices: Compensation, Contracts, and Productivity
  • What is New in Drug Allergy?
  • Updates in Primary Immunodeficiency
  • Rising Pollen Levels via Climate Change: Discovering the Impact on the Allergic Patient
  • Interpreting and Implementing Current Asthma Guidelines

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 7.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Target Audience

Medical professionals who treat patients with allergic and/or immunological conditions:

  • Practicing allergist/immunologists
  • Allergy/immunology Fellows-in-Training
  • Physician assistants
  • Nurses and advanced practice nurses
  • Allied health professionals
  • Primary care physicians
  • Other medical professionals

Learning Objectives

Upon completion of this session, participants should be able to:

  • Identify the economic, societal, and patient related burden of severe asthma.
  • Characterize the comparative efficacy and safety among biologics, macrolides and thermoplasty for severe or difficult-to-control asthma.
  • Compare the efficacy of different reliever therapies in the management of severe asthma.
  • Understand differences found in available practice settings including the employed model, academic practice and private practice models.
  • Describe how Relative Value Units (RVUs) are used in practice to determine productivity.
  • Demonstrate how these different pieces fit together for a healthy practice. Recognize key parts of an employment contract particularly as it relates to different practice structures. Identify and utilize key negotiating tips to improve physician contracts.
  • Review relationships between genetics and immediate and delayed hypersensitivity, and current approach to genetic testing in patients with or at risk for drug hypersensitivity.
  • Discuss utility of diagnostic tools for evaluation of delayed hypersensitivity reactions and demonstrate how testing may aid in reducing the number of potential drugs avoided.
  • Assemble tools available to you for evaluation and treatment of drug allergy.
  • Analyze opportunities for testing beyond immunoglobulin levels and vaccine responses.
  • Discern the differences between Ig products, routes of administration, and choosing the best therapy for your patient.
  • Manage the approach to pulmonary and gastrointestinal manifestations of PIDD.
  • Examine the impact of climate and the resulting change in pollen counts.
  • Assess the data for rising pollens' effects on rhino conjunctivitis and asthma.
  • Recognize climate change impacts on food allergy/nutrition and eczema.
  • Review the evidence for the current use of AIR/MART/SMART.
  • Identify new recommendations from the most recent GINA updates.
  • Overcome barriers in the US healthcare system to implement the new guidelines.
Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines a “ineligible company” as companies whose primary business is producing, marketing, selling, re-selling, or distributing health care goods or services, used by or on patients. Examples of such organizations include: 
 
•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers
  
The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.
Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.
Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified relevant financial relationships have been mitigated.

Course summary
Available credit: 
  • 7.50 AMA PRA Category 1 Credit™
  • 7.50 Attendance
  • 7.50 CBRN
Course opens: 
11/11/2024
Course expires: 
11/10/2027
Part of: 
On Demand ACAAI 2024 Annual Scientific Meeting General Sessions
Rating: 
0

Jay A. Lieberman, MD, FACAAI
Michael S. Blaiss, MD, FACAAI
Giselle S. Mosnaim, MD, MS, FACAAI
Leonard B. Bacharier, MD, FACAAI
Bradley E. Chipps, MD, FACAAI
Melinda M. Rathkopf, MD, MBA, FACAAI
Mariana C. Castells, MD, PhD, FACAAI
Lily Li, MD
Elizabeth Jane Phillips, Professor
David A Khan, MD, FACAAI
Aleena Banerji, MD
Stanley M. Fineman, MD, MBA, FACAAI
Juan Carlos Murillo, MD, FACAAI
Phillip J. Link, MD
Jordan S. Orange, MD, PhD, FACAAI
Charlotte Cunningham-Rundles, MD, PhD
John M. Routes, MD, FACAAI, FCIS
Steve Dorman, MD, FACAAI
Zachary W. Marshall, MD
M. Razi Rafeeq, MD, FACAAI
Andrew Nickels, MD, FACAAI
Warner W. Carr, MD, FACAAI
Kyle Claussen, JD
William C. Anderson, III, MD, FACAAI
Barbara K. Ariue, MD, FACAAI
Brian D. Robertson, MD, FACAAI
Mark C. Stahl, DO, FACAAI
Caroline Clare Horner, MD
Kari Christine Nadeau, MD, PhD
David B. Peden, MD, FACAAI
Jeffrey G. Demain, MD, FACAAI

Available Credit

  • 7.50 AMA PRA Category 1 Credit™
  • 7.50 Attendance
  • 7.50 CBRN
Please login or create an account to take this course.